About
Fragment-based drug discovery platform
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (15)
Anneli Hällgren Ph.D.
Beactica Therapeutics
team_member
Carl-Magnus Andersson Ph.D.
Beactica Therapeutics
team_member
Christina Herder Ph.D.
Beactica Therapeutics
team_member
Erik Walldén
Beactica Therapeutics
team_member
Håkan Wickholm
Beactica Therapeutics
team_member
Jan-Olof Karlsson B.B.A.
Beactica Therapeutics
team_member
Clinical Trials (16)
View allTotal Trials
16
As Lead Sponsor
12
As Collaborator
4
Total Enrollment
1,738
By Phase
EARLY_PHASE1: 1PHASE4: 1PHASE3: 7PHASE1: 3
By Status
COMPLETED: 14TERMINATED: 1UNKNOWN: 1
Clinical Trials Pipeline16 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Today
Hover over trial bars to see details
Recent Trials
NCT03272568Collaborator
Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers
EARLY_PHASE1Completed
3 participants
Started: Feb 14, 2018 · Completed: Dec 31, 2019
NCT03103542Collaborator
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
PHASE4Completed
16 participants
Started: Aug 29, 2017 · Completed: Aug 31, 2020
NCT02546622Collaborator
ATHN 2: Factor Switching Study
N/ACompleted
310 participants
Started: Sep 30, 2015 · Completed: Jun 30, 2020
NCT02502149Lead Sponsor
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
PHASE3Completed
24 participants
Started: Aug 31, 2015 · Completed: Jun 30, 2017
NCT02392156Lead Sponsor
Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
N/ATerminated
3 participants
Started: Jul 31, 2015 · Completed: Dec 31, 2015
Locations (1)
Headquarters
Uppsala, Sweden
Map
Loading map...